Liquidia Co. (NASDAQ:LQDA) Given Consensus Recommendation of “Buy” by Analysts

Liquidia Co. (NASDAQ:LQDA) has received an average rating of “Buy” from the nine ratings firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $25.38.

Several research analysts have weighed in on LQDA shares. Wells Fargo & Company assumed coverage on Liquidia in a research report on Friday, December 20th. They set an “overweight” rating and a $20.00 price objective on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 price target on shares of Liquidia in a research report on Thursday, January 9th. Scotiabank initiated coverage on Liquidia in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $30.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $29.00 target price on shares of Liquidia in a research report on Thursday, November 14th.

Liquidia Price Performance

Shares of LQDA opened at $15.15 on Wednesday. The firm has a market capitalization of $1.28 billion, a PE ratio of -9.29 and a beta of 0.27. Liquidia has a fifty-two week low of $8.26 and a fifty-two week high of $16.99. The company’s 50-day moving average is $12.19 and its 200-day moving average is $11.20.

Insider Activity

In other Liquidia news, insider Rajeev Saggar sold 2,445 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $13.00, for a total transaction of $31,785.00. Following the transaction, the insider now directly owns 267,943 shares in the company, valued at approximately $3,483,259. This represents a 0.90 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Michael Kaseta sold 23,370 shares of Liquidia stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $275,298.60. Following the completion of the sale, the chief financial officer now owns 401,755 shares of the company’s stock, valued at $4,732,673.90. This represents a 5.50 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 73,945 shares of company stock valued at $874,403. Insiders own 30.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Marshall Wace LLP purchased a new stake in shares of Liquidia in the second quarter valued at about $545,000. The Manufacturers Life Insurance Company lifted its position in shares of Liquidia by 25.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,706 shares of the company’s stock worth $272,000 after buying an additional 4,572 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of Liquidia in the 3rd quarter worth approximately $210,000. Sapient Capital LLC bought a new position in shares of Liquidia in the third quarter valued at approximately $1,336,000. Finally, Creative Planning bought a new position in shares of Liquidia in the third quarter valued at approximately $170,000. 64.54% of the stock is owned by institutional investors and hedge funds.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).